Imidazopyrimidine PRC2 Inhibitors via EED Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PRC2 inhibitors targeting the SET domain of EZH2 have limitations in potency, selectivity, cellular efficacy, stability, and safety, especially against EZH2-activating mutations.
Innovation Solution
Development of potent, selective, and orally active compounds that bind to the EED subunit of the PRC2 complex, inhibiting its activity regardless of EZH2 mutation status or expression levels, as represented by Formula (I).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PRC2 inhibitors target the SET domain of EZH2, then PRC2 activity is inhibited, but potency and selectivity are reduced especially against EZH2-activating mutations
Solution Approach 1:
The patent extracts the binding target from the catalytic SET domain of EZH2 and relocates it to the EED subunit. This extraction strategy removes the dependency on EZH2's catalytic activity for inhibitor binding, thereby maintaining potent inhibition even when EZH2 contains activating mutations that compromise SET domain function.
Solution Approach 2:
The patent uses EED as an intermediary binding target between the inhibitor and the PRC2 complex. By binding to EED rather than directly to EZH2's SET domain, the inhibitor achieves a more reliable interaction that persists regardless of EZH2's mutational status, as EED remains functionally intact in mutated EZH2 contexts.
2Productivity
If PRC2 inhibitors target EZH2, then PRC2 activity is inhibited, but cellular efficacy and safety are compromised
Solution Approach 1:
The patent applies local quality by directing the inhibitor's binding affinity specifically toward the EED subunit's unique structural features rather than EZH2's catalytic domain. This localized binding strategy ensures that inhibition occurs at the appropriate complex assembly point, achieving cellular efficacy while avoiding the toxicities associated with direct EZH2 targeting.
3Reliability
If PRC2 inhibitors are developed with high potency, then therapeutic effectiveness is improved, but stability and oral bioavailability are reduced
Solution Approach 1:
The patent employs parameter changes by systematically modifying the chemical structure of EED-binding compounds to optimize pharmacokinetic properties. Through structure-activity relationship analysis, the patent adjusts molecular weight, lipophilicity, and metabolic stability parameters to achieve both high therapeutic effectiveness and improved oral bioavailability.
Data Source
AI summary
Disclosed are compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, disclosed are compounds of Formula (I) and pharmaceutical compositions thereof, and methods of using the compounds and pharmaceutical compositions in, for example, methods of treating cancer.